Assessing use-dependent inhibition of the cardiac Na± current (INa) in the PatchXpress automated patch clamp

Journal of Pharmacological and Toxicological Methods

Volumn 62, Issue 2, 2010, Pages 107-118

  Penniman, Jacob R ^a,b   Kim, David C ^a   Salata, Joseph J ^a   Imredy, John P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b REP Industries Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLECAINIDE; LIDOCAINE; MEXILETINE; SODIUM CHANNEL NAV1.5;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRIC CAPACITANCE; ELECTRODE; ELECTROPHYSIOLOGY; GUINEA PIG; HEART DEPOLARIZATION; HEART RATE; HUMAN; HUMAN CELL; IC 50; MUSCLE CELL; NONHUMAN; OSMOSIS; PATCH CLAMP; PROTEIN EXPRESSION; RISK ASSESSMENT; SODIUM CURRENT;

ACTION POTENTIALS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLECAINIDE; GUINEA PIGS; HEK293 CELLS; HUMANS; LIDOCAINE; MEXILETINE; MUSCLE PROTEINS; MYOCARDIUM; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

CAVIA; HELIOTHIS ZEA VIRUS 1;

EID: 77956064278     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2010.06.007     Document Type: Article

References (29)

1. Anno T., Hondeghem L.M. Interactions of flecainide with guinea-pig cardiac sodium-channels - Importance of activation unblocking to the voltage dependence of recovery. Circulation Research 1990, 66:789-803.
2. Balasubramanian B., Imredy J.P., Kim D., Penniman J., Lagrutta A., Salata J.J. Optimization of Cav1.2 screening with an automated planar patch clamp platform. Journal of Pharmacological and Toxicological Methods 2009, 59:62-72.
3. Bean B.P., Cohen C.J., Tsien R.W. Lidocaine block of cardiac sodium-channels. The Journal of General Physiology 1983, 81:613-642.
4. Benito B., Brugada R., Brugada J., Brugada P. Brugada syndrome. Progress in Cardiovascular Diseases 2008, 51:1-22.
5. Castle N., Printzenhoff D., Zellmer S., Antonio B., Wickenden A., Silvia C. Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. Combinatorial Chemistry & High Throughput Screening 2009, 12:107-122.
6. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obiasmanno D., Barker A.H., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo - The cardiac-arrhythmia suppression trial. The New England Journal of Medicine 1991, 324:781-788.
7. Farre C., Haythornthwaite A., Haarmann C., Stoelzle S., Kreir M., George M., et al. Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. Combinatorial Chemistry & High Throughput Screening 2009, 12:24-37.
8. Greene H.L., Roden D.M., Katz R.J., Woosley R.L., Salerno D.M., Henthorn R.W. The cardiac-arrhythmia suppression trial - 1st CAST ... then CAST-II. Journal of the American College of Cardiology 1992, 19:894-898.
9. Guo L., Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. Journal of Pharmacological and Toxicological Methods 2005, 52:123-135.
10. + current in single canine cardiac Purkinje cells. American Journal of Physiology. Heart and Circulatory Physiology 1992, 262:H1197-H1207.
11. Hanck D.A., Sheets M.F. Site-3 toxins and cardiac sodium channels. Toxicon 2007, 49:181-193.
12. Hartmann H.A., Tiedeman A.A., Chen S.F., Brown A.M., Kirsch G.E. Effects of III-IV linker mutations on human heart Na+channel inactivation gating. Circulation Research 1994, 75:114-122.
13. Korsgaard M.P.G., Strobaek D., Christophersen P. Automated planar electrode electrophysiology in drug discovery: examples of the use of QPatch in basic characterization and high content screening on Na-v, K(Ca)2.3, and K(v)11.1 channels. Combinatorial Chemistry & High Throughput Screening 2009, 12:51-63.
14. Lacerda A.E., Kuryshev Y.A., Chen Y., Renganathan M., Eng H., Danthi S.J., et al. Alfuzosin delays cardiac repolarization by a novel mechanism. The Journal of Pharmacology and Experimental Therapeutics 2008, 324:427-433.
15. Meregalli P.G., Tan H.L., Probst V., Koopmann T.T., Tanck M.W., Bhuiyan Z.A., et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart 2009, 6:341-348.
16. 50 using PatchXpress. Journal of Pharmacological and Toxicological Methods 2009, 60:39-44.
17. Penniman J., Kim D., Salata J., Imredy J. Implementation of a use-dependent cardiac Na+channel inhibition assay on the PatchXpress 7000A automated voltage-clamp. Journal of Pharmacological and Toxicological Methods 2009, 56:e2. (Abstract).
18. Priest B.T., Swensen A.M., McManus O.B. Automated electrophysiology in drug discovery. Current Pharmaceutical Design 2007, 13:2325-2337.
19. Shimizu W., Antzelevitch C., Suyama K., Kurita T., Taguchi A., Aihara N., et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. Journal of Cardiovascular Electrophysiology 2000, 11:1320-1329.
20. Smits J.P.P., Blom M.T., Wilde A.A.M., Tan H.L. Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview. Expert Opinion on Pharmacotherapy 2008, 9:537-549.
21. Stadnicka A., Kwok W.M., Hartmann H.A., Bosnjak Z.J. Effects of halothane and isoflurane on fast and slow inactivation of human heart hH1a sodium channels. Anesthesiology 1999, 90:1671-1683.
22. Suchyna T.M., Markin V.S., Sachs F. Biophysics and structure of the patch and the gigaseal. Biophysical Journal 2009, 97:738-747.
23. Tao H.M., Guia A., Xie B., SantAna D., Manalo G., Xu J., et al. Efficient characterization of use-dependent ion channel blockers by real-time monitoring of channel state. Assay and Drug Development Technologies 2006, 4:57-64.
24. Trepakova E.S., Malik M.G., Imredy J.P., Penniman J.R., Dech S.J., Salata J.J. Application of PatchXpress planar patch clamp technology to the screening of new drug candidates for cardiac KCNQ1/KCNE1 (I Ks) activity. Assay and Drug Development Technologies 2007, 5:617-627.
25. Wang D.W., George A.L., Bennett P.B. Comparison of heterologously expressed human cardiac and skeletal muscle sodium channels. Biophysical Journal 1996, 70:238-245.
26. Yap Y.G., Behr E.R., Camm A.J. Drug-induced Brugada syndrome. Europace 2009, 11:989-994.
27. Yatani A., Akaike N. Blockage of the sodium current in isolated single cells from rat ventricle with mexiletine and disopyramide. Journal of Molecular and Cellular Cardiology 1985, 17:467-476.
28. Zeng H., Penniman J.R., Kinose F., Kim D., Trepakova E.S., Malik M.G., et al. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride. Assay and Drug Development Technologies 2008, 6:235-241.
29. Zimmer T., Surber R. SCN5A channelopathies - An update on mutations and mechanisms. Progress in Biophysics and Molecular Biology 2008, 98:120-136.